An overwhelming majority of Americans believe more research is needed in human genetics and support increased federal funding for research. To echo the public’s need and sentiment, the Society’s vision—people everywhere realize the benefits of human genetics and genomics research—is achievable with sustained and robust funding for the NIH.
Research is essential to continued progress against cancer, but the COVID-19 pandemic has disrupted cancer clinical research and forced the closure of laboratories across the United States. The pandemic underscores the importance of a bipartisan commitment to robust funding for the National Institutes of Health (NIH) and the National Cancer Institutes (NCI). Stable, predictable funding increases—and swift emergency relief—allow AACI’s 102 member cancer centers to continue making new, lifesaving discoveries and delivering high-quality care — even amidst an unprecedented public health emergency.
Researchers who rely on federal grants to sustain their research programs and train their students estimate that they need an additional three to six months of funding to make up for the time and productivity lost due to coronavirus-related closures.
We are in an unprecedented era for cancer research. We have seen tremendous momentum and innovation over the last decade, in large part thanks to the investments made by Congress. However, during the pandemic laboratories have been closed and clinical trials have stopped or struggled to retain enrollees. Investigators are at risk of losing years of research and patients may be missing out on potentially life-saving treatments. Now more than ever, we need Congressional support to restart critical research. We call on Congress to provide emergency funding for the NIH to mitigate the disruptions caused by COVID-19 in addition to a robust increase to baseline funding for the NIH and NCI as an investment towards future cures.
If you think preparedness is expensive, try a pandemic! Emerging infectious diseases like SARS-COV-2 present incalculable costs to our nation and the world. To move beyond a pandemic like COVID-19, Congress must continue to provide robust funding for basic, translational, and clinical microbial research through the NIH. Thanks to past investments in NIH, we have moved with unprecedented speed to develop a vaccine and therapeutics to combat this disease, and we have the ability to develop innovative diagnostics for quicker and more accurate detection of the virus.
The timing of this year’s Rally for Medical Research could not be more important, as Congress determines its pathway forward on the next COVID-19 supplemental and Fiscal Year (FY) 2021 appropriations—hopefully with National Institutes of Health (NIH) research relief within the supplemental or as emergency funding within FY2021 appropriations. While the sight-saving and vision-restoring research funded by the National Eye Institute (NEI) within the NIH holds such promise for all Americans, we cannot forget the impact that clinical practice and laboratory shutdowns has had on investigators, especially early-stage vision researchers who reflect the next generation of scientists.
This is a very exciting time in Alzheimer’s and dementia research. Today, new discoveries are accelerated largely because of unprecedented levels of federal funding and philanthropic investment. This investment has enabled scientists across the country to explore new areas of research.
NIH funding provides the foundation for most of the important discoveries in cancer treatment and research. It is critical to developing the new therapies that will help millions of patients and families in the United States, and around the world, affected every year by this devastating disease. It is critical for continuing scientific discovery, as well as for economic growth and strengthening our global leadership in biomedical research.
NIH funding for fundamental, clinical and public health research has never been more vital as our physicians and scientists tirelessly work to discover innovative treatments and preventive strategies for COVID-19. Increased investment in research for preparedness and improving health is crucial to safeguard future generations and reduce inequities in health outcomes.
This is a transformational time in cancer research and cancer care. Sustained NIH funding, and increased funding for new initiatives such as the NCI Cancer Moonshot, have led to the most exciting discoveries – of the spectrum of mutations that cause cancer and how our own immune systems can be harnessed to fight cancer – that are being translated to new and more effective targeted treatments. It is critical that NIH funding be continually increased and these discoveries disseminated across our nation to assure that all Americans – including racial and ethnic minorities, rural populations, and the underserved – benefit from the fruits of cancer research.
NIH-funded research has facilitated countless advances in genomics, and the joint public-private response to the pandemic is the perfect example of that research’s importance. In order to ultimately deliver better outcomes for patients, we need to continue to support genomic research in fields like oncology, infectious disease, genetic disorders, and pharmacogenomics. We are grateful for Congress’s commitment to this work and urge them to continue to fund this essential research at NIH.
Thanks to the transformative research that is funded by NIH, there is real hope on the horizon for improving outcomes and even curing some forms of cancer and other devastating medical conditions. Innovative new treatments are emerging every day. NIH supports research that improves the health of our entire nation, creates jobs, boosts the economy and ensures that America remains a global leader in health innovation.
The scientists, educators, and clinicians at the nation’s medical schools and teaching hospitals are proud to advance NIH-supported medical research. This research is key to combatting COVID-19, cancer, and all the other conditions that patients face every day. Sustained investment in the NIH is critical to maintaining research momentum that is changing the lives of countless patients and their families.
NIH’s investment in biomedical research has contributed to the development of many cutting-edge treatments that have saved lives and decreased the burden of illness in the United States. Support for our research enterprise is always vital, and especially so now, during the unprecedented COVID-19 pandemic. COVID-19 has shown how critical a well-trained, vibrant, and effective scientific community is in order to respond to known and emerging health threats.
Amid the COVID-19 pandemic, increasing funding for the National Institutes of Health is more critical than ever to effectively respond to the current crisis by developing new treatments, as well as to prevent future outbreaks. We are going to learn a lot of lessons as a result of the COVID-19 pandemic about the epidemiology of this disease, novel types of interventions, including anti-viral drugs and vaccines, and what we need to do as a nation to be prepared for the next pandemic. How we use that information going forward will depend on researchers having steady and predictable support for biomedical research. Scientific discovery and the reliance on scientific data have provided the foundation for tremendous technological and societal advances in the US prior to the current pandemic and will play a critical role in our recovery going forward.
The Rally for Medical Research brings together a diverse range of social, behavioral, and biomedical scientists, patients, caregivers, students, and medical research advocates to send Congress a coordinated, impactful message annually in support of funding the National Institutes of Health (NIH). As important as previous rallies have been, this year’s event is especially critical given the overwhelming challenges that the NIH and its grantees face grappling with the ongoing COVID pandemic while sustaining lifesaving research and research training activities. Population scientists, including demographers, sociologists, and economists, are proud to cosponsor the Rally for Medical Research and work with our colleagues to impress upon Congress the need to continue investing in the NIH.
We thank Members of Congress for their extraordinary commitment to medical research, especially during the past five fiscal years when they have joined together to increase the overall budget for the National Institute of Health by $11.6 billion or 39 percent (since FY 2016). This amazing support has sparked a new wave of scientific discovery and technological innovation, such as allowing us to realize the promise of immunotherapy and combination therapies for an expanding number of cancer indications.
If the COVID-19 pandemic has taught us anything it is the value and power of biomedical research. We would be nowhere without science in this fight and we must come to view our biomedical research infrastructure as a critical aspect of our society that needs and deserves robust funding if we are to overcome the many challenges our world faces in the 21st Century.
Even with recent robust investments in NIH for Covid-19 response, increased funding for medical research remains essential. NIH research improves and saves lives, protects against international health threats, curbs future healthcare spending, maintains global R&D leadership and drives innovation. Research on cancer, Alzheimer’s, diabetes and other deadly diseases cannot wait. Congress must lift the pre-pandemic budget caps and allocate $3 billion for NIH in the FY 2021 appropriations bill. There are too many patients to be patient.
The mental health ramifications of the coronavirus pandemic are immense and growing. It is essential that we prepare for the long-term consequences of COVID-19. APA, in solidarity with other science organizations, urges Congress to provide the National Institutes of Health (NIH) with sustained, predictable funding to support the necessary research addressing the long-lasting implications of the collective trauma facing the population. Research supported by NIH has never been so critical to the recovery and success of our nation.
Now, more than ever, the trajectory of medical innovation is dependent on NIH-funded research across basic, clinical and public health science. We urge Congress to provide stable and predictable funding increases to NIH in support of research to accelerate deepened understanding of diseases and therapeutic breakthroughs to improve public health and patient outcomes.
The National Institute of Nursing Research is on the frontlines of establishing the science that improves practice and policy. Nursing scientists focus on patient and community centered advances that translate to direct cost savings to the healthcare system, patients, and communities. Sustained and increased funding for biomedical and behavioral research is critical to supporting scientific discoveries that promote better health and wellness.
NIH funding has always been essential to advancing our understanding of the immune system and the extraordinary ways it can be used to help prevent, treat, and cure disease. But never before has our research been more urgently needed, and immunologists around the globe are united in their efforts to combat the COVID-19 pandemic. Even as this lifesaving work progresses, NIH funding continues to support immunologists’ efforts to advance research on, and treatments for, other life-threatening and debilitating diseases, including cancer, other infectious diseases (like influenza and HIV/AIDS), and chronic diseases (including Alzheimer’s disease, type 1 diabetes, and heart disease). We urge Congress to continue its strong bipartisan support for NIH and to provide robust additional funding to better understand and treat COVID-19 and to help biomedical researchers whose work has been interrupted or otherwise adversely impacted by the pandemic.
Funding for the National Institutes of Health (NIH) is the lifeblood of basic research and establishes a foundation for the next generation of biomedical breakthroughs that provide hope for patients and their families. The continued leadership and vibrancy of the California and the U.S. life sciences sector is bolstered by the critical scientific advances generated at the NIH and other federally funded research agencies.